Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04457817 · ClinicalTrials.gov registry record
Compensatory Reserve Index (CRI) for Management of COVID-19
A clinical trial, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- 16
- Enrollment target
NCT04457817: Clinical Trial study, sponsored by University of Colorado, Denver.
NCT04457817 is a clinical trial that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04457817 was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.
Primary Outcome
Volume of IV fluid infused during treatment
Interventions
- DEVICE CRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-04-08 |
Why NCT04457817 stopped before completion
NCT04457817 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CRI is the first listed.
NCT04457817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04457817 about?
NCT04457817 is a clinical study titled "Compensatory Reserve Index (CRI) for Management of COVID-19". The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research...
What is the current status of trial NCT04457817?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2020-12-01. Estimated completion is 2021-04-08.
What interventions are being tested in trial NCT04457817?
The interventions under investigation include: CRI (DEVICE).
Who is sponsoring clinical trial NCT04457817?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI